Achieve Life Sciences, Inc. (ACHV) is a specialty biopharmaceutical company dedicated to technological innovations to improve global health conditions. The company focuses primarily on the advancement and commercialization of drugs that cater to serious or life-threatening ailments. Incorporated in 1991 and headquartered in Seattle, Washington, ACHV has, for many years, conducted its operations through a network of scientists and researchers who bring forth innovative solutions to various health problems.
ACHV's flagship product, cytisine, is a plant-based alkaloid that is used to help smokers quit, an advancement that positions Achieve Life Sciences in a pivotal space within the public health concern of tobacco addiction. Cytisine is a naturally occurring plant-based alkaloid that has been used for more than five decades in Central and Eastern Europe in the treatment of nicotine addiction.
ACHV is committed to the development and provision of solutions that aid in smoking cessation. Its cytisine development program aims to deliver a lineup of products that can alleviate tobacco dependence, bolstering its position in the biopharmaceutical industry. Publicly traded on the NASDAQ, ACHV has enhanced its global reach over the years, evident in its significant foothold in the Canadian market and its collaborative relationship with University College London for clinical trials.
The company is guided by a board of members who bring in-depth knowledge and extensive experience in the development and commercialization of pharmaceutical products. This has driven the company’s success in research and development, investor relations, and strategic planning within a highly competitive pharmaceutical landscape.
With a coherent corporate social responsibility strategy, Achieve Life Sciences, Inc. is deeply committed to enhancing clinical outcomes and improving global health standards. The company’s dedication to addressing critical health challenges while maintaining robust corporate and social governance makes it a vanguard in the biopharmaceutical industry.
ACHV continues to invest in the development and endorsement of therapies which address significant health issues. By conducting rigorous clinical trials and maintaining high standards in all its operations, Achieve Life Sciences, Inc. continuously exhibits its commitment to technological innovation, health solutions, and value creation for its shareholders. The company's dedication to developing viable solutions for significant health conditions, like tobacco addiction, reflects its commitment to the betterment of public health and its robust corporate ethos.